CHRONIX BIOMEDICAL, INC

Chronix Biomedical, Inc. is a molecular diagnostics company offering laboratory developed blood tests to doctors for cancer screening supplemental evaluations and monitoring cancer through its own certified laboratories. Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany. Currently, Chronix Biomedical is offering 4 different tests.

Delta Dot treatment outcome evaluation test

A blood test that indicates whether a treatment is working in one to two cycles of therapy with over 90% positive predictive value.

CNI cancer evaluation
test

A blood test that reveals mutations mostly seen in patients with cancer.

Second Opinion™ prostate cancer evaluation test

A blood test for men with elevated PSA that reveals the mutations mostly seen in patients with prostate cancer.

Second Opinion™ breast cancer evaluation test

A blood test for patients with abnormal mammograms or lumps that reveals the mutations mostly seen in patients with breast cancer.

CHRONIX NEWS

  • advanced cancer diagnostics - liquid biopsy

The pioneers behind Advanced Cancer Diagnostics whose cancer cure is ‘five years away’

December 5th, 2016|0 Comments

Evening Standard writes about Advanced Cancer Diagnostics...

  • blood-test-could-identify-aggressive-prostate-cancer

Blood test could identify aggressive prostate cancer

November 8th, 2016|0 Comments

The Times: thousands of men with prostate cancer could be saved from unnecessary operations thanks to a blood test [...]

  • chronix-biomedical-updates-on-progress-with-prostate-and-pancreatic-cancer-validation-studies

Chronix Biomedical updates on progress with prostate and pancreatic cancer validation studies

November 3rd, 2016|0 Comments

Chronix Biomedical, Inc., a developer of novel cancer blood-based molecular diagnostics, is pleased to update investors on the progress of two clinical studies [...]

VIDEOS

Prof. P. Radziszewski – New generation oncological biomarkers – focusing on Chronix company

We present a lecture delivered at the  5th Polish women [...]

Paul Freiman, Chairman, Chronix – about CNI Tests

#TheTurningPointInCancerFight

Michael Oellerich, MD, Professor of George-August-University Göttingen

#TheTurningPointInCancerFight

Order tests

EVENTS

Advanced Cancer Diagnostics Showcasingat 2016 NCRI Cancer Conference 6-9 November 2016

November 3rd, 2016|0 Comments

Chronix Biomedical’s Ireland & UK distributors Advanced Cancer Diagnostics will be attending and showcasing the latest Chronix diagnostic tests: [...]

  • asco-2016

ASCO 2016

November 3rd, 2016|0 Comments

“Tumor cell-free DNA copy number instability (CNI) predicts therapeutic response to immunotherapy prior to cycle 2” , was presented [...]

PUBLICATIONS

  • Dr hab. n. med. Jakub Dobruch FEBU - liquid biopsy

Dr hab. n. med. Jakub Dobruch, FEBU – Liquid Biopsy

November 14th, 2016|0 Comments

Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016

Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.

Prof. P. Radziszewski – New generation oncological biomarkers – focusing on Chronix company

November 3rd, 2016|0 Comments

We present a lecture delivered at the  5th Polish women and men health debate according to Medical guidelines – [...]

  • first-published-results-in-breast-cancer

First published results in breast cancer

November 3rd, 2016|0 Comments

Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.

Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.

“The knowledge that we have gained over the past year now suggests to us that we are able to provide to doctors and their patients the ability to diagnose at the most earliest stage the presence of cancer in their body.”
Howard Urnovitz, CEO of Chronix Biomedical for The Times
“We believe our cancer blood tests will lead to a world where no one dies unnecessarily of cancer.”
Howard Urnovitz, CEO of Chronix Biomedical